Infosys agrees to acquire Optimum Healthcare IT for $465m in its second-largest deal, targeting AI-led transformation of US provider market

Infosys (NSE: INFY | BSE: 500209 | NYSE: INFY) has entered a definitive agreement to acquire Optimum Healthcare IT, a Jacksonville Beach, Florida-based healthcare digital transformation and consulting firm, for up to $465 million in an all-cash transaction announced on March 25, 2026. The deal, Infosys’s second-largest acquisition by value, gives the Bengaluru-headquartered IT services major full ownership of a firm that generated $275.9 million in revenue for the year ended December 2025 and brings more than 1,600 healthcare specialists to Infosys’s workforce. The acquisition is part of a broader $560 million dual-deal day for Infosys, which simultaneously announced the $95 million purchase of insurance technology firm Stratus. For Infosys, whose NYSE-listed American Depositary Receipts closed at $13.08 on March 24 and are trading around $13.38 in pre-market activity on the announcement day, the Optimum Healthcare IT transaction signals a deliberate acceleration into the US healthcare provider market at a moment when AI-driven transformation of clinical and administrative infrastructure is moving from pilot to production.

What does the $465 million Infosys acquisition of Optimum Healthcare IT mean for US health system digitisation at scale?

Optimum Healthcare IT has built its reputation primarily in the provider segment, working with hospitals and health systems on electronic health record advisory, implementation, and managed services. Its standing as a Best in KLAS healthcare digital transformation firm reflects the industry’s own scoring of client satisfaction and delivery quality, a credential that carries weight in a sector where buyer confidence is paramount and implementation failures are well-documented and expensive. The firm holds Elite ServiceNow partner status, won the 2026 ServiceNow Partner of the Year Award, and also carries Premier AWS and Microsoft Azure partner designations, alongside a Workday Services partnership. That multi-cloud, multi-platform positioning is not accidental. Healthcare providers are not standardising on single-vendor infrastructure, and a consulting partner that can operate credibly across ServiceNow, AWS, Azure, and Workday is positioned to capture transformation spend wherever it flows.

For Infosys, the strategic logic is straightforward but requires execution discipline to realise. The company has been building out Infosys Topaz, its AI-first suite, and Infosys Cobalt, its cloud migration and management portfolio, as cross-sector capability layers. Healthcare has been an identified growth vertical, but Infosys’s existing provider relationships and delivery footprint in the US healthcare system have lagged its presence in financial services, retail, and manufacturing. Optimum Healthcare IT addresses that gap directly, adding a ready-made client base, domain specialists, and an established delivery model without Infosys needing to build market position organically over five to seven years.

How does the deal price compare to Optimum Healthcare IT revenue and what are the valuation implications for healthcare IT M&A?

At up to $465 million for a business that reported $275.9 million in FY25 revenue, Infosys is paying a revenue multiple of approximately 1.7 times. The consideration structure includes upfront payment and earnouts, a common mechanism in services acquisitions that ties a portion of the price to post-acquisition performance, aligning seller incentives with integration outcomes. Management incentives and retention bonuses sit outside the $465 million figure, meaning the total economic cost of securing and retaining Optimum Healthcare IT’s leadership and key personnel will be higher than the headline number. In a business where client relationships are frequently personal and portable, that additional retention spend is arguably as important as the acquisition price itself.

The multiple is consistent with the current pricing environment for mid-market healthcare IT services assets with recurring managed services revenues and verifiable domain depth. It is not an outlier price, but it is also not a distressed acquisition. Infosys is paying for a genuinely differentiated asset, and the competitive process run by adviser Harris Williams would have ensured that multiple strategic and financial buyers had the opportunity to table offers. The fact that Infosys secured it suggests either a strong strategic premium over financial sponsors or a seller preference for the scale and healthcare investment commitment Infosys could offer.

How does Infosys Topaz AI and Cobalt cloud strategy integrate with Optimum Healthcare IT’s existing provider delivery model?

The integration thesis rests on a specific sequence. Optimum Healthcare IT has the front-door relationships with health systems and hospitals. Infosys has the platform depth, AI capability through Topaz, and cloud infrastructure capacity through Cobalt. The combination is designed to move healthcare providers from discrete consulting engagements, where Optimum Healthcare IT advises on an EHR implementation or a ServiceNow workflow deployment, into broader end-to-end transformation programmes spanning cloud migration, AI-enabled clinical decision support, cybersecurity, and application modernisation.

That is a more ambitious commercial model than either organisation runs independently today. Optimum Healthcare IT’s 1,600-plus specialists are deep in healthcare workflows and provider operations. What they have not had is a parent company capable of putting a global delivery centre, AI development teams, and enterprise-scale cloud engineering resources behind those client relationships. Infosys provides exactly that infrastructure. The risk, which is consistent across all professional services M&A, is whether cross-selling a large technology services portfolio into Optimum Healthcare IT’s client base can be accomplished without disrupting the trust, responsiveness, and delivery quality that made those clients choose Optimum Healthcare IT in the first place.

What are the competitive implications of Infosys entering the US healthcare provider segment with a specialist acquisition?

The US healthcare IT services market is contested by a combination of large generalist IT firms, pure-play healthcare consultancies, and the major EHR vendors’ own services arms. Accenture, Deloitte, Cognizant, and Wipro all compete for healthcare provider transformation budgets, and several have made targeted acquisitions of their own to build provider-specific depth. Cognizant’s TriZetto acquisition and its sustained investment in the payer segment illustrates how that playbook has worked in insurance; the provider side has been somewhat slower to consolidate at the specialist level.

Infosys’s move signals that the provider consolidation phase is now underway. By acquiring what is widely regarded as one of the stronger independent healthcare IT transformation firms in the US market, Infosys has positioned itself to compete for large health system deals that require both domain credibility and scale delivery. Competitors without equivalent provider-specific assets will face pressure either to acquire similar capabilities or to risk ceding ground in a segment that is spending heavily on technology as regulatory and reimbursement pressures force operational efficiency at scale.

How does the Infosys INFY stock perform heading into the Optimum Healthcare IT deal close and what does the market reaction indicate?

Infosys shares on the NSE were trading around INR 1,279 to 1,290 on March 25 to 26, 2026, up modestly on the announcement day after a period of sustained pressure. The NYSE-listed ADR had closed at $13.08 on March 24, within a 52-week range of approximately $12.57 to $30.00, reflecting a stock that has given back substantial gains from a year ago. On the NSE, the 52-week range spans roughly INR 1,215 to INR 1,728, putting the current price closer to the lower end of that band despite the positive pre-market moves on deal day. The stock’s P/E of approximately 17 to 18 times reflects a market that is pricing Infosys as a mature IT services business facing headwinds from slower discretionary technology spending, rather than as a high-growth AI platform company.

The market’s measured response to the Optimum Healthcare IT announcement is rational. At $465 million, the deal is large but not transformative in the context of Infosys’s roughly $19.85 billion in trailing twelve-month revenue. It adds approximately 1.4 percentage points to the revenue base on an annualised basis. The more important question is whether the acquisition contributes to closing the gap between Infosys’s current valuation and the analyst consensus target of around $17 to $18 on the ADR. That depends on whether management can demonstrate within the next two to three quarters that healthcare provider revenue is growing, that cross-sell is converting, and that the deal is contributing to, rather than diluting, margin. The Q1 FY2027 earnings update, expected around April 2026, will be the first read on how the market is assessing deal integration progress.

What integration and execution risks does Infosys face in absorbing a specialist healthcare consulting firm of this size?

Healthcare IT services firms are human-capital businesses. The value Infosys is acquiring is principally the expertise, client relationships, and institutional knowledge of Optimum Healthcare IT’s 1,600-plus employees, not a proprietary software platform or a portfolio of patents. That means retention is not a secondary concern but the primary integration risk. The earnout structure embedded in the $465 million consideration is one mechanism to address that, but earnouts can also create friction if targets are structured in ways that make Optimum Healthcare IT’s leadership feel their autonomy is constrained or that the metrics are misaligned with client-first outcomes.

The statements from co-founders Gene Scheurer and Jason Mabry emphasise continuity of team, leadership involvement, and the existing client-first service model. That framing is standard in acquisition communications, but it also reflects a genuine concern that the acquiring organisation needs to take seriously. Healthcare provider clients chose Optimum Healthcare IT in part because it operates with the responsiveness and accountability that large IT services firms can struggle to replicate once a smaller firm is absorbed into a global delivery model. Infosys will need to find a structural arrangement that allows Optimum Healthcare IT to retain enough autonomy to preserve its market positioning while integrating sufficiently with Infosys platforms and delivery infrastructure to unlock the strategic rationale for the deal.

Why is AI-led healthcare transformation a strategic priority for Indian IT services firms targeting US market growth in 2026?

US healthcare is among the largest and most structurally complex sectors in the global economy, spending over $4.5 trillion annually with persistent inefficiencies in data interoperability, administrative cost, and clinical decision support. The combination of increasing regulatory pressure on providers, a shift toward value-based care reimbursement models, and the arrival of credible AI tools for clinical and operational workflows has created a multi-year investment cycle that is largely independent of the broader macro environment affecting discretionary technology spending.

For Indian IT services firms whose US revenue growth has moderated from peak rates as financial services and retail clients pause larger transformation programmes, healthcare represents one of the more structurally durable spending pools available. Infosys is not alone in recognising this. The Optimum Healthcare IT acquisition accelerates a positioning shift that the company has been signalling through organic investment in its healthcare vertical and through its AI platform strategy. The simultaneous Stratus acquisition, focused on insurance technology, suggests Infosys is approaching the full healthcare economy rather than just the provider segment, covering both the care delivery and the financing sides of the market.

Key takeaways: What the Infosys acquisition of Optimum Healthcare IT means for the company, its rivals, and the US healthcare IT sector

• Infosys is paying up to $465 million in cash for Optimum Healthcare IT, its second-largest acquisition, at a revenue multiple of approximately 1.7 times on reported FY25 revenue of $275.9 million. The structure includes earnouts aligned to post-deal performance.
• The transaction is part of a single-day $560 million deployment, with Stratus acquired for $95 million concurrently, signalling a deliberate acceleration of Infosys’s US market positioning in healthcare and insurance technology.
• Optimum Healthcare IT brings over 1,600 domain specialists and an established provider client base that Infosys lacked. The deal bypasses years of organic market-building in one of the most difficult-to-enter segments in US enterprise technology.
• The integration thesis is cross-sell dependent: Infosys’s Topaz AI and Cobalt cloud platforms need to be brought to bear on Optimum Healthcare IT’s existing client relationships for the deal to generate returns above the acquisition multiple.
• Human capital retention is the primary integration risk. Earnout structures and co-founder continuity statements suggest Infosys understands this, but execution will determine whether key talent and client relationships remain intact through the transition.
• Infosys’s NYSE ADR (INFY) trades near its 52-week low, with a 52-week range of approximately $12.57 to $30.00. The market’s modest positive reaction to the announcement reflects both the deal’s strategic logic and uncertainty about near-term margin impact and integration execution.
• Competitor pressure is real. Accenture, Cognizant, Deloitte, and Wipro all have healthcare ambitions and will now need to respond to a materially stronger Infosys position in US provider transformation.
• Optimum Healthcare IT’s multi-platform credentials across ServiceNow, AWS, Azure, and Workday align with the fragmented technology environments of large health systems, making the acquired business immediately deployable across a range of client infrastructure configurations.
• The Q1 FY2027 earnings call, expected around April 16, 2026, will be the first opportunity for Infosys management to provide revenue contribution guidance and integration milestones. Investor focus will be on margin dilution, cross-sell pipeline, and deal close timeline.
• The broader signal is sector-directional: US healthcare provider digital transformation has entered a consolidation phase among IT services M&A, and mid-market specialist firms with verifiable domain depth and recurring revenue are likely to attract further acquisition interest.